Inhibrx (INBX)
(Delayed Data from NSDQ)
$34.46 USD
-0.24 (-0.69%)
Updated May 20, 2024 04:00 PM ET
After-Market: $34.46 0.00 (0.00%) 7:58 PM ET
4-Sell of 5 4
F Value F Growth C Momentum F VGM
Balance Sheet
Fiscal Year End for Inhibrx, Inc falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 278 | 274 | 131 | 129 | 12 |
Receivables | 1 | 0 | 1 | 1 | 0 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 |
Other Current Assets | 17 | 6 | 7 | 3 | 4 |
Total Current Assets | 295 | 280 | 139 | 132 | 16 |
Net Property & Equipment | 6 | 3 | 3 | 3 | 3 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 0 | 0 | 0 | 0 | 0 |
Deposits & Other Assets | 3 | 3 | 2 | 0 | 0 |
Total Assets | 308 | 291 | 150 | 144 | 26 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 11 | 8 | 9 | 13 | 3 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 4 |
Current Portion Capital Leases | 2 | 2 | 2 | 2 | 1 |
Accrued Expenses | 43 | 17 | 10 | 13 | 5 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 0 | 0 | 2 | 3 | 8 |
Total Current Liabilities | 56 | 28 | 22 | 31 | 21 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 1 | 1 |
Convertible Debt | 0 | 0 | 0 | 0 | 30 |
Long-Term Debt | 207 | 202 | 70 | 29 | 0 |
Non-Current Capital Leases | 1 | 3 | 5 | 7 | 7 |
Other Non-Current Liabilities | 0 | 0 | 0 | 0 | 61 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 264 | 233 | 98 | 68 | 120 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 657 | 430 | 280 | 221 | -24 |
Retained Earnings | -614 | -372 | -227 | -145 | -69 |
Other Equity | 0 | 0 | 0 | 0 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 44 | 58 | 52 | 75 | -94 |
Total Liabilities & Shareholder's Equity | 308 | 291 | 150 | 144 | 26 |
Total Common Equity | 44 | 58 | 52 | 75 | -94 |
Shares Outstanding | 47.20 | 43.50 | 37.90 | 37.70 | NA |
Book Value Per Share | 0.92 | 1.33 | 1.38 | 2.00 | 0.00 |
Fiscal Year End for Inhibrx, Inc falls in the month of December.
All items in Millions except Per Share data.
3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 252 | 278 | 337 | 192 | 234 |
Receivables | 3 | 1 | 0 | 0 | 0 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 |
Other Current Assets | 19 | 17 | 26 | 11 | 9 |
Total Current Assets | 275 | 295 | 363 | 203 | 244 |
Net Property & Equipment | 7 | 6 | 3 | 3 | 2 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 0 | 0 | 0 | 0 | 0 |
Deposits & Other Assets | 5 | 3 | 3 | 3 | 3 |
Total Assets | 289 | 308 | 373 | 213 | 254 |
Liabilities & Shareholders Equity | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 15 | 11 | 8 | 10 | 11 |
Current Portion Long-Term Debt | 4 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 2 | 2 | 2 | 2 | 2 |
Accrued Expenses | 51 | 43 | 26 | 20 | 20 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 0 | 0 | 0 | 0 | 0 |
Total Current Liabilities | 72 | 56 | 36 | 31 | 33 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 205 | 207 | 206 | 204 | 203 |
Non-Current Capital Leases | 0 | 1 | 0 | 2 | 3 |
Other Non-Current Liabilities | 0 | 0 | 0 | 0 | |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 277 | 264 | 243 | 238 | 239 |
Shareholders Equity | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 704 | 657 | 650 | 444 | 436 |
Retained Earnings | -692 | -614 | -520 | -468 | -421 |
Other Equity | 0 | 0 | 0 | 0 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 12 | 44 | 130 | -25 | 15 |
Total Liabilities & Shareholder's Equity | 289 | 308 | 373 | 213 | 254 |
Total Common Equity | 12 | 44 | 130 | -25 | 15 |
Shares Outstanding | 52.20 | 47.20 | 43.60 | 43.60 | 43.60 |
Book Value Per Share | 0.22 | 0.92 | 2.97 | -0.57 | 0.35 |